{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-24-000041","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.831219+00:00","generated_at":"2026-06-04T04:18:36.770414+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Lifecore provides FY2024 guidance: rev $125M-$130M; 9M rev $90.5M (+25% YoY)","bullets":["Nine-month revenue through Feb 24, 2024: $90.5M vs restated $72.1M in prior year, up 26%.","Full-year FY2024 guidance: revenue $125M-$130M, adjusted EBITDA $13.5M-$16.9M.","Development portfolio grows to 33 projects (+4 YoY); prospective pipeline has 68 opportunities.","Capacity expansion: theoretical capacity to triple to ~70M units by FY2027; 5-head filler GMP-ready Aug 2024.","Alcon HA supply agreement: capacity up 38% in FY2024; further 20% yield improvement expected in FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-24-000041","json":"https://secwatch.observer/filing/0001005286-24-000041.json","markdown":"https://secwatch.observer/filing/0001005286-24-000041.md","text":"https://secwatch.observer/filing/0001005286-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000041/0001005286-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000041/lndc-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:18:36.770414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}